Boxer Capital’s Cymabay Therapeutics CBAY Stock Holding History

Boxer Capital’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-4,000,000	Closed	-$17.4M	–	103
2021 Q2	$17.4M	Hold	4,000,000	–	–	0.62%	52
2021 Q1	$18.2M	Hold	4,000,000	–	–	0.62%	47
2020 Q4	$23M	Hold	4,000,000	–	–	0.74%	38
2020 Q3	$29M	Buy	4,000,000 +2,000,000	+100%	+$10.7M	1%	29
2020 Q2	$6.98M	Hold	2,000,000	–	–	0.31%	52
2020 Q1	$2.96M	Hold	2,000,000	–	–	0.2%	57
2019 Q4	$3.92M	Buy	2,000,000 +750,000	+60%	+$2.82M	0.22%	46
2019 Q3	$6.4M	Hold	1,250,000	–	–	0.46%	40
2019 Q2	$8.95M	Hold	1,250,000	–	–	0.77%	24
2019 Q1	$16.6M	Sell	1,250,000 -844,000	-40%	-$8.98M	1.92%	16
2018 Q4	$16.5M	Hold	2,094,000	–	–	2.04%	14
2018 Q3	$23.2M	Hold	2,094,000	–	–	2.57%	13
2018 Q2	$28.1M	Sell	2,094,000 -618,986	-23%	-$7.75M	3.18%	12
2018 Q1	$35.2M	Buy	2,712,986 +1,700,000	+168%	+$21.1M	3.76%	12
2017 Q4	$9.32M	Hold	1,012,986	–	–	1.7%	16
2017 Q3	$8.16M	Buy	1,012,986 +587,986	+138%	+$3.98M	1.86%	14
2017 Q2	$2.45M	Sell	425,000 -352,202	-45%	-$1.5M	0.58%	23
2017 Q1	$3.34M	Buy	+777,202	New	+$2.23M	0.73%	19

Other funds holding CBAY

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Boxer Capital's CBAY Position: Q3 2021 in Review

Boxer Capital sold out of Cymabay Therapeutics (CBAY) in Q3 2021, closing a stake of 4,000,000 shares — an estimated $17.4M sold.

Boxer Capital first reported a position in CBAY in Q1 2017 and held it in 18 quarters. The position peaked at $35.2M in Q1 2018. 113 funds tracked by Wall St. Rank hold CBAY as of Q3 2021.

Boxer Capital reported no remaining Cymabay Therapeutics position as of Q3 2021 after selling out during the quarter.
Boxer Capital sold 4,000,000 Cymabay Therapeutics shares in Q3 2021, an estimated $17.4M.
Boxer Capital first reported a position in Cymabay Therapeutics in Q1 2017 and held it in 18 quarters.
Boxer Capital's Cymabay Therapeutics position peaked at $35.2M in Q1 2018.
113 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q3 2021.

Based on Boxer Capital's 13F filing for Q3 2021, filed 15 Nov 2021.